We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical ... read more Featured Products: More products

Download Mobile App





Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers

By LabMedica International staff writers
Posted on 02 Aug 2018
Print article
Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Snibe Diagnostic (ShenZhen, China), a leading provider of chemiluminescence immunoassay solutions, presented its range of instruments at the 70th AACC (Annual Scientific Meeting & Clinical Lab Expo), which took place in Chicago, Illinois, USA, from Jul. 29 to Aug. 2, 2018.

Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.

The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.